|Day Low/High||47.57 / 49.84|
|52 Wk Low/High||41.23 / 52.83|
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
Knowing when to continue to fish or cut bait is something that develops over time in this space.
New $70 million investment in 105-megawatt solar panel installation in North Carolina underscores 'Circular for Zero' commitment to environment
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Gilead Sciences is partnering with Novo Nordisk to help combat liver disease.
Jim Cramer says these downgrades may be well-reasoned, but he wants to know if they're correct.
Jim Cramer weighs in on Ollie's Bargain Outlet, Novo Nordisk, Avnet, Cabot Corp., Helmerich & Payne, Amarin, Golar LNG, Nio and more.
I would add to them on any significant dips in the market.
One of pharma's biggest CEO's talks M&A action on the exchange.
Global stocks were mixed Wednesday, with stronger-than-expected trade data from China, as well as the expectation of further stimulus from Beijing, boosting shares in Asia while softer earnings in Europe held down gains for stocks on the Continent.
We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
Pharma firm's new diabetes drug showed positive test results.
The Danish company's shares are enjoying their best day since May 2.
Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.